Galmed Pharmaceuticals (GLMD) AI Stock Analysis

• Market Cap: $2.98M
• Dividend Yield: N/A
• Average Volume (3M): 1.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: N/A
• EPS Growth: 71.41%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -9.17
• Shares Outstanding: 2,258,034
• 10 Day Avg. Volume: 143,324
• 30 Day Avg. Volume: 1,784,939
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Galmed Pharmaceuticals faces significant financial challenges with no revenue and continuous operational losses. The technical indicators signal a strong bearish trend, and the valuation metrics highlight ongoing unprofitability with a negative P/E ratio. Despite a debt-free balance sheet, the company's reliance on equity financing amid operational inefficiencies poses substantial risks.

Galmed Pharmaceuticals Business Overview & Revenue Model

Company Description

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutic solutions to address liver diseases. The company's primary product candidate, Aramchol, is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Galmed Pharmaceuticals operates within the biotechnology and pharmaceutical sectors, with its research and development efforts aimed at addressing unmet medical needs in the area of liver health.

How the Company Makes Money

Galmed Pharmaceuticals makes money primarily through the development and potential commercialization of its lead product candidate, Aramchol. As a clinical-stage company, Galmed does not currently generate product revenues. Instead, the company relies on funding from public and private investors to finance its research and development activities. In the future, Galmed aims to generate revenue through the successful commercialization of Aramchol, which could include sales, licensing agreements, or partnerships with larger pharmaceutical companies. Collaborations and partnerships could provide upfront payments, milestone payments, and royalties based on sales performance once Aramchol or any other product candidates receive regulatory approval and are brought to market.

Galmed Pharmaceuticals Financial Statement Overview

Summary

Galmed Pharmaceuticals faces significant financial challenges with consistently negative revenue and operational losses. The balance sheet is strong with no debt, but negative cash flows indicate cash burn and reliance on external funding.

Income Statement

Galmed Pharmaceuticals shows consistently negative revenue with no income from operations over the years. The company's EBIT and EBITDA margins are negative, reflecting ongoing operational losses. This highlights significant profitability challenges and an inability to generate revenue.

Balance Sheet

The company maintains a healthy equity position with no debt, resulting in a debt-to-equity ratio of zero. However, the persistent negative net income leads to weak return on equity. The equity ratio is relatively stable, indicating a solid asset base.

Cash Flow

Cash flow from operations is negative, indicating cash burn and reliance on external financing. However, the company has managed to maintain a positive cash position. The free cash flow remains negative, showing cash outflows exceeding cash inflows.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-89.00K	-31.00K	-35.00K	-42.00K	-39.00K	-35.00K
	EBIT
-6.79M	7.49M	-17.65M	-32.88M	-30.21M	-22.38M
	EBITDA
-6.70M	-6.87M	-17.62M	-32.84M	-30.17M	-22.34M
	Net Income Common Stockholders
-6.32M	-6.91M	-18.57M	-31.95M	-27.61M	-18.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
718.00K	12.64M	13.79M	34.81M	50.89M	75.49M
	Total Assets
0.00	16.63M	16.56M	36.60M	52.38M	77.14M
	Total Debt
0.00	41.00K	44.00K	229.00K	216.00K	352.00K
	Net Debt
718.00K	-2.82M	-1.97M	-2.65M	-6.73M	-15.58M
	Total Liabilities
0.00	2.75M	3.14M	6.11M	8.23M	7.29M
	Stockholders Equity
-1.98M	13.88M	13.42M	30.50M	44.15M	69.85M
Cash Flow		Free Cash Flow
-4.81M	-6.14M	-18.50M	-32.90M	-26.33M	-14.95M
	Operating Cash Flow
-4.81M	-6.14M	-18.50M	-32.89M	-26.29M	-14.94M
	Investing Cash Flow
4.72M	800.00K	17.56M	11.46M	16.54M	6.68M
	Financing Cash Flow
8.34M	6.18M	70.00K	17.37M	768.00K	143.00K

Galmed Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLMD, the sentiment is Negative. The current price of 1.32 is below the 20-day moving average (MA) of 1.72, below the 50-day MA of 2.08, and below the 200-day MA of 3.33, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 30.85 is Neutral, neither overbought nor oversold. The STOCH value of 10.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GLMD.

Galmed Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AKRO	60 Neutral	$2.84B	―	-39.22%	―	―	-31.37%
MDGL	54 Neutral	$7.00B	―	-80.35%	―	―	-10.89%
Sector *	48 Neutral	$6.36B	1.19	-46.31%	2.67%	19.41%	1.23%
VKTX	42 Neutral	$2.50B	―	-17.90%	―	―	-10.27%
BLRX	34 Underperform	$10.26M	―	-69.11%	―	502.92%	88.20%
GALT	33 Underperform	$85.29M	―	48.74%	―	―	-1.60%
GLMD	27 Underperform	$2.98M	―	-49.77%	―	―	71.41%